Chemoproteomics Reveals Glaucocalyxin A Induces Mitochondria‐Dependent Apoptosis of Leukemia Cells via Covalently Binding to VDAC1

• Published in: Advanced biology Vol. 8; no. 2; pp. e2300538 - n/a
• Main Authors: An, Yehai, Zhang, Qian, Chen, Yu, Xia, Fei, Wong, Yin‐Kwan, He, Hengkai, Hao, Mingjing, Tian, Jiahang, Zhang, Xiaoyong, Luo, Piao, Wang, Jigang
• Format: Journal Article
• Language: English
• Published: Germany 01.02.2024
• Subjects: chronic myelogenous leukemia; Glaucocalyxin A; mitochondrial apoptosis; VDAC; VDAC; chronic myelogenous leukemia; Glaucocalyxin A; mitochondrial apoptosis
• ISSN: 2701-0198; 2701-0198
• DOI: 10.1002/adbi.202300538

Chronic myelogenous leukemia (CML) that is resistant to tyrosine kinase inhibitors is one of the deadliest hematologic malignancies, and the T315I mutation in the breakpoint cluster region‐Abelson (BCR‐ABL) kinase domain is the most prominent point mutation responsible for imatinib resistance in CML. Glaucocalyxin A (GLA), a natural bioactive product derived from the Rabdosia rubescens plant, has strong anticancer activity. In this study, the effect and molecular mechanism of GLA on imatinib‐sensitive and imatinib‐resistant CML cells harboring T315I mutation via a combined deconvolution strategy of chemoproteomics and label‐free proteomics is investigated. The data demonstrated that GLA restrains proliferation and induces mitochondria‐dependent apoptosis in both imatinib‐sensitive and resistant CML cells. GLA covalently binds to the cysteine residues of mitochondrial voltage‐dependent anion channels (VDACs), resulting in mitochondrial damage and overflow of intracellular apoptotic factors, eventually leading to apoptosis. In addition, the combination of GLA with elastin, a mitochondrial channel VDAC2/3 inhibitor, enhances mitochondria‐dependent apoptosis in imatinib‐sensitive and ‐resistant CML cells, representing a promising therapeutic approach for leukemia treatment. Taken together, the results show that GLA induces mitochondria‐dependent apoptosis via covalently targeting VDACs in CML cells. GLA may thus be a candidate compound for the treatment of leukemia. Glaucocalyxin A covalently targets mitochondrial channel VDACs and then induces mitochondria‐dependent apoptosis via a combined deconvolution strategy of chemoproteomics and label‐free proteomics.